Panagene said Thursday that it has received sales approval for PANARealTyper STD, a sexually transmitted diseases detection kit, from the Ministry of Food and Drug Safety.

The product uses the company’s proprietary PanarealTyper technology and detects 12 pathogens that cause sexually transmitted infections in a single test.

PANARealTyper is a multi-detection technology that enables multiple diagnostics by overcoming the limit of the number of simultaneously detectable targets in real-time PCR (real-time polymerase chain reaction) equipment.

Such technology gives the device an excellent reproducibility and sensitivity, which in turn, makes it possible to diagnose various infectious disease bacteria accurately.

The company has applied the technology to its HPV detection kits and is selling the product to various domestic and international medical institutions.

Also, as part of expanding the application of technology, Panagene plans to apply for the ministry’s approval for HPV and carbapenem antibiotic resistance diagnostic kit after completing clinical trials this year.

“We are going to launch various molecular diagnostic products using our technology,” a company official said. “Starting with the STD product, we will release various pipeline products and sell them in the domestic and overseas market.”

Panagene CEO Kim Sung-kee said, “We will do our best to lead the market in the field of infection diagnosis to keep the reputation as a leading company in the domestic tumor diagnosis industry.”